Compare
BridgeBio Pharma, Inc. vs Travere Therapeutics, Inc. vs Mirum Pharmaceuticals, Inc. vs Nature's Sunshine Products Inc
| Latest fiscal year | BridgeBio Pharma, Inc. BBIO | Travere Therapeutics, Inc. TVTX | Mirum Pharmaceuticals, Inc. MIRM | Nature's Sunshine Products Inc NATR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $502.08M | $490.73M | $521.31M | $480.14M |
| Revenue growth (YoY) | +126.3% | +110.5% | +54.7% | +5.7% |
| Gross margin | n/a | n/a | n/a | 72.4% |
| Operating margin | -104.2% | -12.8% | -4.2% | 5.2% |
| Net margin | -146.0% | -5.2% | -4.5% | 4.3% |
| Net income | -$732.94M | -$25.55M | -$23.36M | $20.45M |
| EPS (Diluted) | -$3.78 | -$0.29 | -$0.47 | $1.06 |
| Operating cash flow | -$445.91M | $37.78M | $55.83M | $35.32M |
| Free cash flow | -$447.01M | n/a | $54.87M | $28.84M |
| Cash & equivalents | $570.12M | $93.03M | $296.68M | $93.89M |
| Total assets | $936.02M | $605.19M | $842.81M | $261.15M |
| Total liabilities | $3.01B | $490.36M | $528.12M | $99.59M |
| Shareholders' equity | -$2.09B | $114.83M | $314.69M | $161.55M |
| Return on year-end equity | n/a | -22.2% | -7.4% | 12.7% |
| Shares outstanding | 194.77M | 90.92M | 51.90M | 17.51M |
Revenue, most recent five fiscal years
| Fiscal year | BridgeBio Pharma, Inc. | Travere Therapeutics, Inc. | Mirum Pharmaceuticals, Inc. | Nature's Sunshine Products Inc |
|---|---|---|---|---|
| Latest | $502.08M Ended 2025-12-31 | $490.73M Ended 2025-12-31 | $521.31M Ended 2025-12-31 | $480.14M Ended 2025-12-31 |
| 1 year earlier | $221.90M Ended 2024-12-31 | $233.18M Ended 2024-12-31 | $336.89M Ended 2024-12-31 | $454.36M Ended 2024-12-31 |
| 2 years earlier | $9.30M Ended 2023-12-31 | $145.24M Ended 2023-12-31 | $186.37M Ended 2023-12-31 | $445.32M Ended 2023-12-31 |
| 3 years earlier | $77.65M Ended 2022-12-31 | $109.46M Ended 2022-12-31 | $77.06M Ended 2022-12-31 | $421.91M Ended 2022-12-31 |
| 4 years earlier | $69.72M Ended 2021-12-31 | $131.84M Ended 2021-12-31 | $19.14M Ended 2021-12-31 | $444.08M Ended 2021-12-31 |